Literature DB >> 16443669

Fetal morphine metabolism and clearance are constant during late gestation.

Marianne Garland1, Kirsten M Abildskov, Samantha Taylor, Kenza Benzeroual, Casper S Caspersen, Sylvia E Arroyo, Tung-Wah Kiu, Boris Reznik, Piper Weldy, Salha S Daniel, Raymond I Stark.   

Abstract

Fetal metabolism significantly contributes to the clearance of drugs from the fetus. To understand how the changes in fetal metabolism expected in late gestation alter fetal drug clearance, serial measurements of morphine metabolism were made in the fetal baboon over the latter third of gestation. Clearance and metabolism were evaluated in the context of fetal growth, onset of labor, and the administration of classical enzyme induction agents. Morphine, a probe substrate for the enzyme uridine diphosphate glucuronosyltransferase 2B7 (UGT2B7), was continuously infused to chronically catheterized fetal baboons while measuring morphine, morphine-3-beta-glucuronide, and morphine-6-beta-glucuronide concentrations. In some animals, intermittent infusions of the metabolites provided estimates of metabolite clearance and, hence, the rate of formation of metabolites and metabolic clearance. Overall, metabolic clearance of morphine from the fetus was 27 +/- 9.0 ml x min(-1) or 32% of total clearance. This is similar to the overall clearance in the adult baboon when standardized to weight. No change in any measure of metabolism or clearance of morphine or its glucuronide metabolites was found with gestational age, the presence of labor, or administration of UGT enzyme induction agents. Interpreting these findings using a physiologically based approach suggests that the intrinsic clearance of the fetal liver toward morphine is of sufficient magnitude that fetal hepatic clearance is flow-limited. The implication of a high intrinsic clearance is for significant placento-hepatic first-pass metabolism when drugs are administered to the mother. The previously held view of the "inadequacy of perinatal glucuronidation" needs to be reconsidered.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16443669     DOI: 10.1124/dmd.105.007567

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  8 in total

Review 1.  Endogenous opiates and behavior: 2006.

Authors:  Richard J Bodnar
Journal:  Peptides       Date:  2007-09-11       Impact factor: 3.750

2.  Application of Model Informed Precision Dosing to Address the Impact of Pregnancy Stage and CYP2D6 Phenotype on Foetal Morphine Exposure.

Authors:  Sarah Badaoui; Ashley M Hopkins; A David Rodrigues; John O Miners; Michael J Sorich; Andrew Rowland
Journal:  AAPS J       Date:  2021-01-06       Impact factor: 4.009

3.  Maternal buprenorphine dose, placenta buprenorphine, and metabolite concentrations and neonatal outcomes.

Authors:  Marta Concheiro; Hendreé E Jones; Rolley E Johnson; Robin Choo; Diaa M Shakleya; Marilyn A Huestis
Journal:  Ther Drug Monit       Date:  2010-04       Impact factor: 3.681

4.  Pharmacokinetics of fluoxetine in pregnant baboons (Papio spp.).

Authors:  Rivka L Shoulson; Raymond L Stark; Marianne Garland
Journal:  J Am Assoc Lab Anim Sci       Date:  2014-11       Impact factor: 1.232

5.  Placental transfer and fetal elimination of morphine-3-beta-glucuronide in the pregnant baboon.

Authors:  Marianne Garland; Kirsten M Abildskov; Tung-Wah Kiu; Salha S Daniel; Piper Weldy; Raymond I Stark
Journal:  Drug Metab Dispos       Date:  2008-06-19       Impact factor: 3.922

6.  Correlations of maternal buprenorphine dose, buprenorphine, and metabolite concentrations in meconium with neonatal outcomes.

Authors:  S L Kacinko; H E Jones; R E Johnson; R E Choo; M A Huestis
Journal:  Clin Pharmacol Ther       Date:  2008-08-13       Impact factor: 6.875

7.  Molecular cloning of the baboon UDP-glucuronosyltransferase 2B gene family and their activity in conjugating morphine.

Authors:  Kirsten Abildskov; Piper Weldy; Marianne Garland
Journal:  Drug Metab Dispos       Date:  2010-01-13       Impact factor: 3.922

Review 8.  Delivery technologies for in utero gene therapy.

Authors:  Rohan Palanki; William H Peranteau; Michael J Mitchell
Journal:  Adv Drug Deliv Rev       Date:  2020-11-09       Impact factor: 15.470

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.